Baldwin D S, Montgomery S A
University Department of Psychiatry, University of Southampton, UK.
Int Clin Psychopharmacol. 1995 Nov;10(4):239-44.
Although neuroleptic drugs have proven value in the management of patients with schizophrenia, the existing drugs are far from ideal. The pharmacological profile of olanzapine (LY 170053, Lilly) in animal models suggests that it may be an effective antipsychotic drug in humans, with the potential for a reduced incidence of desirable extra-pyramidal side effects, compared to existing neuroleptics. The results of this first investigation of olanzapine in schizophrenic patients indicate that it has efficacy as an antipsychotic compound, relieving positive and negative features of schizophrenia. Olanzapine appears to have an acceptable degree of overall tolerability, and may be associated with a low incidence of extrapyramidal tract symptoms. It does not appear to be free of adverse effects on liver function.
尽管抗精神病药物在治疗精神分裂症患者方面已被证明具有价值，但现有的药物远非理想。奥氮平（LY 170053，礼来公司）在动物模型中的药理学特性表明，它可能是一种对人类有效的抗精神病药物，与现有的抗精神病药物相比，有可能降低锥体外系副作用的发生率。这项对精神分裂症患者进行的首次奥氮平研究结果表明，它作为一种抗精神病化合物具有疗效，可缓解精神分裂症的阳性和阴性症状。奥氮平似乎具有可接受的总体耐受性，并且可能与锥体外系症状的低发生率相关。它似乎并非对肝功能没有不良影响。
